SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

GlaxoSmithKline Pharmaceuticals informs about disclosure

09 Apr 2025 Evaluate
GlaxoSmithKline Pharmaceuticals has informed that the Company has received the CIT-Appeal Order under Section 250 read with section 43(3) for Assessment Year 2004-2005, issuing income tax refund of Rs 49.54 cr (including interest) on 8th April 2025.

The above information is a part of company’s filings submitted to BSE.

Glaxosmithkline Phar Share Price

2484.70 5.75 (0.23%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×